Depression and ADHD symptoms drove heavier cannabis use in Swiss adults, but anxiety and psychosis did not
Among 360 regular cannabis users in Switzerland, only depression and ADHD symptom severity predicted how often and how much cannabis people used after adjusting for other factors.
Quick Facts
What This Study Found
After adjusting for age, gender, education, alcohol, and other substance use, only depression and ADHD remained significantly associated with both frequency (p=.006, p=.034) and quantity (p=.037, p=.019). Anxiety and psychosis associations disappeared after adjustment.
Key Numbers
360 participants. Depression predicted frequency (p=.006) and quantity (p=.037). ADHD predicted frequency (p=.034) and quantity (p=.019). Anxiety and psychosis: not significant after adjustment.
How They Did This
Cross-sectional study of 360 regular cannabis users in Basel, Switzerland, using validated measures (PHQ-9, GAD-7, ASRS, IRAOS, CUDIT-R). Multiple regression adjusted for demographics and substance use.
Why This Research Matters
The selective association with depression and ADHD but not anxiety or psychosis suggests specific self-medication patterns, with implications for which psychiatric populations need targeted cannabis screening.
The Bigger Picture
The self-medication hypothesis operates selectively. If people with depression and ADHD specifically escalate use, targeted interventions for these groups could be more effective than general cannabis education.
What This Study Doesn't Tell Us
Cross-sectional design. Self-selected sample interested in regulated cannabis access. Self-report measures. Swiss sample may not generalize globally.
Questions This Raises
- ?Would treating depression and ADHD reduce cannabis consumption?
- ?Why do anxiety symptoms not independently predict cannabis use after adjustment?
Trust & Context
- Key Stat:
- the only psychiatric symptom domains that independently predicted both cannabis use frequency and quantity after adjustment
- Evidence Grade:
- Well-powered sample with validated measures and appropriate adjustment, though cross-sectional design limits causal claims.
- Study Age:
- 2024 publication.
- Original Title:
- Cannabis use and its association with psychopathological symptoms in a Swiss adult population: a cross-sectional analysis.
- Published In:
- Frontiers in public health, 12, 1356988 (2024)
- Authors:
- Mosandl, Christoph Felix(2), Baltes-Flückiger, Lavinia, Kronschnabel, Jens(2), Meyer, Maximilian, Guessoum, Adrian, Herrmann, Oliver, Vogel, Marc, Walter, Marc, Pichler, Eva-Maria
- Database ID:
- RTHC-05571
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
Do people with mental health problems use more cannabis?
In this study, depression and ADHD specifically predicted heavier use. Anxiety and psychosis lost significance after controlling for other factors.
Is cannabis self-medication for ADHD?
Some people with ADHD report cannabis helps with symptoms, and ADHD severity predicted heavier use here. Cross-sectional data cannot determine whether cannabis provides genuine relief or worsens ADHD.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-05571APA
Mosandl, Christoph Felix; Baltes-Flückiger, Lavinia; Kronschnabel, Jens; Meyer, Maximilian; Guessoum, Adrian; Herrmann, Oliver; Vogel, Marc; Walter, Marc; Pichler, Eva-Maria. (2024). Cannabis use and its association with psychopathological symptoms in a Swiss adult population: a cross-sectional analysis.. Frontiers in public health, 12, 1356988. https://doi.org/10.3389/fpubh.2024.1356988
MLA
Mosandl, Christoph Felix, et al. "Cannabis use and its association with psychopathological symptoms in a Swiss adult population: a cross-sectional analysis.." Frontiers in public health, 2024. https://doi.org/10.3389/fpubh.2024.1356988
RethinkTHC
RethinkTHC Research Database. "Cannabis use and its association with psychopathological sym..." RTHC-05571. Retrieved from https://rethinkthc.com/research/mosandl-2024-cannabis-use-and-its
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.